Muscle loss 6 months after surgery predicts poor survival of patients with non-metastatic colorectal cancer

被引:5
|
作者
Zhang, Liang [1 ,2 ]
Guan, Junjie [3 ]
Ding, Chao [2 ]
Feng, Min [2 ]
Gong, Longbo [1 ]
Guan, Wenxian [2 ]
机构
[1] Xuzhou Cent Hosp, Dept Gastrointestinal Surg, Xuzhou, Peoples R China
[2] Nanjing Med Univ, Dept Gen Surg, Drum Tower Clin Med Coll, Nanjing, Jiangsu, Peoples R China
[3] Nanjing Univ Tradit Chinese Med, Jiangsu Prov Hosp Chinese Med, Dept Gen Surg, Affiliated Hosp, Nanjing, Jiangsu, Peoples R China
来源
FRONTIERS IN NUTRITION | 2022年 / 9卷
关键词
colorectal cancer; sarcopenia; skeletal muscle loss; visceral adipose tissue; survival; BODY-COMPOSITION; SKELETAL-MUSCLE; SURGICAL OUTCOMES; OBESITY PARADOX; CACHEXIA; IMPACT;
D O I
10.3389/fnut.2022.1047029
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
BackgroundMuscle loss is a common characteristic of cancer-related malnutrition and a predictor of poorer prognosis in oncological patients. This study evaluated the association between altered body composition 6 months after surgery and the prognosis in patients with non-metastatic colorectal cancer. Materials and methodsA total of 314 patients who underwent elective curative surgery were enrolled in the study. The third lumbar CT images on preoperative and 6-months postoperative were collected to calculate the skeletal muscle index (SMI), visceral adiposity index (VATI), and subcutaneous adiposity index (SATI). Sarcopenia was defined by the cut-off values reported in the literature, and risk factors affecting overall survival (OS) and disease-free survival (DFS) in CRC were analyzed using Cox regression models. ResultsEighty-two of 314 patients (26.1%) with CRC were diagnosed with sarcopenia before surgery, the preoperative sarcopenia was not significantly associated with the prognosis of CRC patients. There were significant differences in frequency of complications between patient groups according to sarcopenia (41.5 vs. 21.4%, p = 0.004). The Postoperative LOS (11.21 +/- 3.04 vs. 8.92 +/- 2.84, p < 0.001) was longer in the sarcopenia group than in the non-sarcopenia group, and 30-d readmission (24.4 vs. 6.0%, p < 0.001) was higher in the sarcopenia group compared to the non-sarcopenia group. In multivariate analysis, 6-months SMI loss > 10% after surgery was independently associated with poorer OS [hazard ratio (HR) = 3.74; 95% confidence interval (CI) 1.96 to 7.12; P < 0.001] and DFS (HR = 3.33; 95% CI, 1.71 to 6.47; P < 0.001). SMI changes were moderately correlated with changes in body mass index (BMI) (R = 0.47, P < 0.001). Conclusion6-months muscle loss after surgery may affect overall and disease-free survival and was an independent predictor of prognosis in patients with CRC.
引用
收藏
页数:9
相关论文
共 50 条
  • [31] Reconsidering the TNM stage in non-metastatic colorectal cancer according to the survival paradox
    Zheng, P.
    Ma, D.
    Gao, X.
    ANNALS OF ONCOLOGY, 2023, 34 : S129 - S129
  • [32] Revisiting the prognostic relevance of muscle mass among non-metastatic colorectal cancer
    Abdel-Rahman, Omar
    Cheung, Winson Y.
    TRANSLATIONAL GASTROENTEROLOGY AND HEPATOLOGY, 2018, 3
  • [33] High preoperative serum ferritin predicted poor prognosis in non-metastatic colorectal cancer
    Hong Tingting
    Shen Di
    Chen Xiaoping
    Wu Xiaohong
    Hua Dong
    SAUDI MEDICAL JOURNAL, 2017, 38 (03) : 268 - 275
  • [34] Preoperative nutritional status and overall survival among non-metastatic colorectal cancer patients: The ColoCare Study
    Gigic, Biljana
    Damerell, Victoria
    Lin, Tengda
    Ose, Jennifer
    Kahlert, Christoph
    Figueiredo, Jane C.
    Li, Christopher I.
    Schneider, Martin
    Shibata, David
    Siegel, Erin M.
    Toriola, Adetunji T.
    Ulrich, Cornelia M.
    CANCER RESEARCH, 2024, 84 (06)
  • [35] Influence of Postoperative Changes in Sarcopenia on Long-Term Survival in Non-Metastatic Colorectal Cancer Patients
    Lee, Chungyeop
    Park, In-Ja
    Kim, Kyung-Won
    Shin, Yongbin
    Lim, Seok-Byung
    Kim, Chan-Wook
    Yoon, Yong-Sik
    Lee, Jong-Lyul
    Yu, Chang-Sik
    Kim, Jin-Cheon
    CANCERS, 2021, 13 (10)
  • [36] Castrate testosterone predicts biochemical relapse free survival in non-metastatic prostate cancer
    Ozyigit, G.
    Hurmuz, P.
    Yuce, D.
    Akyol, F.
    RADIOTHERAPY AND ONCOLOGY, 2019, 133 : S440 - S440
  • [37] Increased Plasma Superoxide Radical in Patients with Non-Metastatic Colorectal Cancer
    Assimakopoulos, Stelios F.
    Grintzalis, Konstantinos
    Papapostolou, Ioannis
    Thomopoulos, Konstantinos C.
    Georgiou, Christos D.
    GASTROENTEROLOGY RESEARCH, 2008, 1 (01) : 45 - 48
  • [38] Non-metastatic breast cancer specific-survival of patients after treatment with adjuvant chemotherapy
    Duarte Cintra, Jane Rocha
    Guerra, Maximiliano Ribeiro
    Bustamante-Teixeira, Maria Teresa
    REVISTA DA ASSOCIACAO MEDICA BRASILEIRA, 2008, 54 (04): : 339 - 346
  • [39] Tumor Response Ratio Better Predicts Overall Survival in Neoadjuvant Chemotherapy Patients With Non-Metastatic Breast Cancer
    Miller, Marian
    Ottesen, Rebecca
    Niland, Joyce
    Kruper, Laura L.
    Chen, Steven L.
    Vito, Courtney
    ANNALS OF SURGICAL ONCOLOGY, 2014, 21 : 81 - 82
  • [40] Prognostic Nomogram for Disease-Specific Survival in Patients with Non-metastatic Ampullary Carcinoma After Surgery
    Li, Huang-bao
    Zhao, Feng-qing
    Zhou, Jun
    ANNALS OF SURGICAL ONCOLOGY, 2019, 26 (04) : 1079 - 1085